Search clinical trials for: Vascular Endothelial Growth Factor (VEGF) antibody

Total 85675 results

Chulalongkorn University

Completed

Topical Bevacizumab for Preventing Recurrent Pterygium

Pterygium | Bevacizumab | VEGF | Anti-VEGF

Thailand
Universitair Ziekenhuis Brussel
Merck Serono International SA

Unknown

Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)

Pregnancy | Embryonic Development | VEGF

Belgium
Sisli Hamidiye Etfal Training and Research Hospital

Completed

Lung Ultrasound in PD Patients (LUSiPD)

Peritoneal Dialysis | Hypervolemia | VEGF Overexpression

Turkey
IRCCS National Neurological Institute "C. Mondino...

Not yet recruiting

The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients

Multiple Sclerosis Relapse
Bayer

Completed

Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration (REVIEW)

Macular Degeneration

Portugal
Kyungpook National University Hospital

Completed

Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy

Age-Related Macular Degeneration

Korea, Republic of
Beni-Suef University

Unknown

Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction (VEGF in FGR)

Foetal Growth Restriction

Egypt
Bagcilar Training and Research Hospital

Completed

Vascular Endothelial Growth Factor Levels in Ectopic Pregnancy (VEGF)

Complication Following Ectopic Pregnancy

Turkey
Weill Medical College of Cornell University

Withdrawn

Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)

Respiratory Distress Syndrome, Adult

United States
Marquette General Health System
Upper Michigan Brain Tumor Center

Withdrawn

Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients

Glioma | Meningioma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
National Taiwan University Hospital

Unknown

Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions

Oral Cancer

Taiwan
First Affiliated Hospital of Wenzhou Medical University

Completed

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors

AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs

China
Roswell Park Cancer Institute
GlaxoSmithKline

Active, not recruiting

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Neoplasm

United States
Oslo University Hospital

Completed

Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept (Eylea-2014)

Exudative Age-related Macular Degeneration
Northwestern University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Atypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial Meningioma

United States
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0502)

Gastrointestinal Stromal Tumor

United States, Canada
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma

United States
Seoul St. Mary's Hospital

Unknown

Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy

Polypoidal Choroidal Vasculopathy

Korea, Republic of
National Cancer Institute (NCI)

Completed

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin Melanoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Malignant Ovarian Epithelial Tumor | Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor | Ovarian Granulosa Cell Tumor | Ovarian Sex Cord-Stromal Tumor | Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell...

United States
National Cancer Institute (NCI)

Completed

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Solid Neoplasm

United States
Wake Forest University Health Sciences

Terminated

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Retinal Vein Occlusion

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditions

United States
Jaeb Center for Health Research
National Eye Institute (NEI); National Institutes of Health (NIH); Regeneron...

Completed

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR (AB)

Proliferative Diabetic Retinopathy | Vitreous Hemorrhage

United States, Canada
Northwestern University

Completed

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Neurofibromatosis Type 1 | Neurofibromatosis Type 2 | Adult Ependymoma | Recurrent Adult Brain Tumor | Acoustic Schwannoma | Adult Anaplastic Meningioma | Adult Grade I Meningioma | Adult Grade II Meningioma | Adult Meningeal Hemangiopericytoma | Adult Papillary Meningioma

United States
Genentech, Inc.

Completed

A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers

Foot Ulcer
Fondation Ophtalmologique Adolphe de Rothschild

Suspended

Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease (COATS-VEGF)

Retinal Telangiectasis | Coats Disease

France
National Cancer Institute (NCI)
Fox Chase Cancer Center

Completed

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma (Mel47)

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma

United States
Kuopio University Hospital
University of Eastern Finland

Completed

EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease (KAT301)

Myocardial Infarction | Angina Pectoris

Finland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8 | Ampulla of Vater Adenocarcinoma | Stage III Ampulla... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

Glioma | Glioblastoma

United States
M.D. Anderson Cancer Center
Eli Lilly and Company

Completed

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

Recurrent Brain Neoplasm

United States
IVI Madrid

Completed

Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors

Vascular Endothelial Growth Factor Overexpression
Medical University of Vienna

Withdrawn

Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?

Age-Related Macular Degeneration | Choroidal NeoVascularization

Austria
University of Sao Paulo General Hospital

Completed

Serum VEGF as a Tubal Pregnancy Marker

Pregnancy, Ectopic

Brazil
National Cancer Institute (NCI)

Active, not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Glioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain Neoplasm

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Vaginal Squamous Cell Carcinoma, Not Otherwise Specified | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Recurrent Merkel Cell Carcinoma | Recurrent Nasopharynx Carcinoma | Appendix Adenocarcinoma and other conditions

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Microsatellite Stable | Stage III Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer AJCC v7 | Mismatch Repair Protein Proficient

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada
Groupe Hospitalier Pitie-Salpetriere

Completed

Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN. (VEGAN)

Vascular Diseases | Cardiac Complication

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube... and other conditions

United States

Search clinical trials for: Vascular Endothelial Growth Factor (VEGF) antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations